Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA

被引：0

作者：

Grohe, C. ^{[1
]}

Tsuboi, M. ^{[2
]}

Wu, Y. ^{[3
,4
]}

John, T. ^{[5
]}

Majem, M. ^{[6
]}

Wang, J. ^{[7
]}

Kato, T. ^{[8
]}

Goldman, J. ^{[9
]}

Kim, S. ^{[10
]}

Yu, C. ^{[11
,12
]}

Vu, H. ^{[13
]}

Mukhametshina, G. ^{[14
]}

Akewanlop, C. ^{[15
]}

de Marinis, F. ^{[16
]}

Shepherd, F. ^{[17
]}

Urban, D. ^{[18
,19
]}

Stachowiak, M. ^{[20
]}

Balanos, A. ^{[20
]}

Huang, X. ^{[20
]}

Herbst, R. ^{[21
,22
]}

Kern, J. ^{[15
,23
]}

机构：

[1] Evangel Lungenklin Berlin Buch, Berlin, Germany

[2] Natl Canc Ctr Hosp East, Kashiwa, Japan

[3] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China

[4] Guangdong Acad Med Sci, Guangzhou, Peoples R China

[5] Austin Hlth, Heidelberg, Australia

[6] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[7] Chinese Acad Med Sci, Beijing, Peoples R China

[8] Kanagawa Canc Ctr, Asahi Ward, Asahi, Japan

[9] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA

[10] Asan Med Ctr, Seoul, South Korea

[11] Natl Taiwan Univ Hosp, Taipei, Taiwan

[12] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[13] Cho Ray Hosp, Ho Chi Minh City, Vietnam

[14] Republican Clin Oncol Ctr, Kazan City, Russia

[15] Siriraj Hosp, Bangkok, Thailand

[16] IRCCS, European Inst Oncol Ieo, San Giovanni Rotondo, Italy

[17] Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON, Canada

[18] Sheba Med Ctr, Tel Hashomer, Israel

[19] Sackler Fac Med, Tel Hashomer, Israel

[20] Astrazeneca, Cambridge, England

[21] Yale Sch Med, New Haven, CT USA

[22] Yale Canc Ctr, New Haven, CT USA

[23] Kwm Missio Clin, Wurzburg, Germany

来源：

PNEUMOLOGIE | 2023年 / 77卷

关键词：

D O I：

10.1055/s-0043-1760904

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

FV 96

引用

页码：S17 / S17

页数：1

共 50 条

[21] Osimertinib as adjuvant therapy in patients (pts) with stage IBIIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA
Tsuboi, Masahiro
John, Thomas
Grohe, Christian
Majem, Margarita
Goldman, Jonathan Wade
Kim, Sang-We
Marmol, Dominika
Rukazenkov, Yuri
Wu, Yi-Long
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)
[22] Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC
Wu, Y.
John, T.
Grohe, C.
Majem, M.
Goldman, J.
Kim, S.
Kato, T.
Laktionov, K. K.
Vu, H. V.
Wang, Z.
Lu, S.
Lee, K. Y.
Akewanlop, C.
Yu, C.
De Marinis, F.
Bonanno, L.
Domine, M.
Shepherd, F.
Zeng, L.
Atasoy, A.
Herbst, R.
Tsuboi, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S113 - S114
[23] IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC
Wang, Jie
Fan, Yun
Fang, Jian
He, Jianxing
Liu, Yunpeng
Tao, Min
Altorki, Nasser
Felip, Enriqueta
Wakelee, Heather
Vallieres, Eric
Belleli, Rossella
McNally, Virginia
Bennett, Elizabeth
Gitlitz, Barbara J.
Zhou, Caicun
CANCER RESEARCH, 2024, 84 (07)
[24] Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
Wang, Jie
Wu, Yi-Long
Lu, Shun
Wang, Qun
Li, Shanqing
Zhong, Wen-Zhao
Wang, Qiming
Li, Wei
Wang, Buhai
Chen, Jun
Cheng, Ying
Duan, Hongbing
Li, Gaofeng
Shan, Li
Liu, Yangbo
Liu, Jing
Huang, Xiangning
Bolanos, Ana
He, Jie
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
[25] Three-Year Safety, Tolerability, and Health- Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
John, Thomas
Grohe, Christian
Goldman, Jonathan W.
Shepherd, Frances A.
de Marinis, Filippo
Kato, Terufumi
Wang, Qun
Su, Wu-Chou
Choi, Jin Hyuk
Sriuranpong, Virote
Melotti, Barbara
Fidler, Mary J.
Chen, Jun
Albayaty, Muna
Stachowiak, Marta
Taggart, Sarah
Wu, Yi-Long
Tsuboi, Masahiro
Herbst, Roy S.
Majem, Margarita
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (09) : 1209 - 1221
[26] IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
Altorki, N.
Felip, E.
Zhou, C.
Vallieres, E.
Moiseyenko, V.
Smolin, A.
Rittmeyer, A.
Vereshchako, R.
Perol, M.
Schutte, W.
Fang, J.
Tao, M.
Teixeira, E.
Kim, Y.
Gitlitz, B.
Bennett, E.
Mcnally, V.
Wu, F.
Deng, Y.
Wakelee, H.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S845 - S846
[27] Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
Chen, Ping
Yang, Qing
Li, Yinfeng
Jing, Xiaomei
Chen, Jing
FRONTIERS IN ONCOLOGY, 2022, 12
[28] Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
Wu, Yi-Long
John, Thomas
Grohe, Christian
Majem, Margarita
Goldman, Jonathan W.
Kim, Sang-We
Kato, Terufumi
Laktionov, Konstantin
Vu, Huu Vinh
Wang, Zhijie
Lu, Shun
Lee, Kye Young
Akewanlop, Charuwan
Yu, Chong-Jen
de Marinis, Filippo
Bonanno, Laura
Domine, Manuel
Shepherd, Frances A.
Zeng, Lingmin
Atasoy, Ajlan
Herbst, Roy S.
Tsuboi, Masahiro
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (03) : 423 - 433
[29] Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC
Remon, Jordi
Hendriks, Lizza E. L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 368 - 370
[30] Postoperative Chemotherapy-Use and Results of the ADAURA-Study: Osimertinib as adjuvant Therapy in resected EGFR-mutated NSCLC Patients
Grohe, C.
Wu, Y. L.
John, T.
Majem, M.
Goldman, J. W.
Kim, S.
Kato, T.
Laktionov, K.
Vu, H. V.
Wang, Z.
Lu, S.
Lee, K.
Akewanlop, C.
Yu, C. J.
De Marinis, F.
Bonanno, L.
Domine, M.
Shepherd, F. A.
Zeng, L.
Atasoy, A.
Herbst, R. S.
Tsuboi, M.
Engel-Riedel, W.
PNEUMOLOGIE, 2021, 75 : S18 - S19

← 1 2 3 4 5 →